Centogene NV (CNTG)       2.65  +0.28 (+11.81%)

CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential...

CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO...

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18...

CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework

CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases...

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

Newly established WGS recommendations published in the European Journal of Human Genetics Collaborative initiative leverages CENTOGENE’s differentiated...

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential...

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract...

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong...

CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Rise and shine, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday!

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company...

CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical...

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...

CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...

CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan

Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globallyEUR 15 million private...

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creation...

CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer

Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor...

CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development

CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AINPC is a...

Centogene Becomes Oversold (CNTG)

CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery

Leveraging AI to Accelerate the Path From Diagnosis to Cure...

CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...